Beijing Novogene Biotechnology Co., Ltd. was established in 2020, focusing on the development and production of active pharmaceutical ingredients and intermediates. Its main products include empagliflozin intermediates, tiotropium bromide intermediates, rivaroxaban intermediates, and others. The company has a research and development center, with most products independently developed, and holds multiple domestic and international patents for various products. The factory is equipped with comprehensive production facilities, including over 30 enamel and stainless steel reactors with capacities ranging from 500 to 5000 liters and a total volume exceeding 600 m3. Industrial production has been achieved for reactions and processes with high operational difficulty, including butyllithium reactions, Grignard reactions, hydrogenation reactions, low-temperature reactions (–80°C), high-pressure reactions (1-2 MPa), and high-vacuum distillation (≤ 0.5 mmHg). While developing internationally mainstream drugs, the company also places great emphasis on custom processing services for clients and actively develops niche products. A relatively complete quality assurance system compliant with GMP standards has been established, including an inspection system equipped with Agilent HPLC, GC, UV, and other instruments, as well as an experienced quality management team. The company operates an active pharmaceutical ingredient production base that meets GMP standards.